The market outlook from the perspective of many biotech CEOs is grim. When the investment environment stabilized following a ...

SAN JOSE -- A Stanford University genetics professor has paid nearly $30 million in restitution after a judge determined that he misled investors in a now-dissolved biotechnology company he founded.

A new report from Pitchbook suggests we’re in for a period of more sustainable investing, with VC firms continuing to create ...

A prominent genetics professor at Stanford University in the US ... claimed he misled them whist persuading them to invest $20 million in the biotech, set up to develop a candidate therapy for ...

A Stanford University genetics professor has paid nearly $30 million in restitution after a judge determined that he misled investors in a now-dissolved biotechnology company he founded.

Last year was a difficult one for ex-Stanford president Marc Tessier-Lavigne ... But the once-chief scientific officer of Genentech is now back in biotech. Marc Tessier-Lavigne, Ph.D. (Tessier ...

Altos Labs, backed by $3 billion from Jeff Bezos and others, has snagged a small Peninsula company focused on one approach to ...

hosted “Impulse,” among Stanford’s premier biotechnology conferences, bringing together a community of students building products and technology for healthcare and biomedicine. The annual ...

At Stanford’s Drug Discovery Symposium, biotech bigwigs spoke openly this week about how the scientific ecosystem that trains the industry’s workforce and produces many of the discoveries ...

Biotech has long been recognized as one of the most speculative industries to invest in, precisely because most of its early-stage companies rely on securing funding for research and development ...